The Phase 3 Program in MESI – PEAK and PINNACLE study design Weeks D1 4 8 12 16 20 24 28 32 36 40 44 48 KSI-101 5 mg KSI-101 10 mg Sham Primary endpoint KSI-101 5 mg injection Sham injection KSI-101 10 mg injection Individualized treatment (PRN) Sham PRN Fixed monthly dosing Individualized dosing Key inclusion criteria • Macular edema secondary to inflammation (MESI) • Diagnosis of active or inactive non-infectious intraocular inflammation, acute or chronic • Active leakage as evidenced by fluorescein angiogram • OCT CST of ≥320 microns • BCVA score ≤78 and ≥25 (~20/25 to 20/320 Snellen) Individualized treatment criteria (Week 24-44) • Increase in OCT CST ≥50 μm compared to lowest previous measurement, or • OCT CST >320 μm Primary endpoint BCVA change from baseline to the average of Week 20 and 24 Key secondary endpoint Proportion of patients in whom BCVA had improved by ≥15 letters from baseline to 24 weeks Actively Enrolling 72